Skip to main content
Caplight Logo









Axoltis Pharma

Axoltis Pharma

Private
Clermont-FerrandHealthcare & Life Scienceshttps://www.axoltis.com/

Last Round

Series A

Dec 2, 2025

Est. Valuation

$37.63M

Total Funding Raised

$23.32M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Axoltis Pharma is a biotechnology company that develops innovative drugs for neurodegenerative and neurotraumatic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

ALSamyotrophic lateral sclerosisneurodegenerative diseaseclinical stage biotechpeptide therapeuticfirst-in-class drugblood-brain barrierneuroprotectionorphan drugpharma licensingdrug developmentBBBParkinson's diseaseAlzheimer's diseaseneurotherapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axoltis Pharma Comparables

Compare Axoltis Pharma with similar companies based on industry and business-model similarity.

Axoltis Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AL-S Pharma AG
81%
Primary Peptides, Inc.
80%
Revalesio
79%

Axoltis Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 2, 2025
SeedJun 15, 2016

Key People

Founding team and executive leadership

Luca Bolliger

Chief Business Officer, Independent Supervisory Board Member

Executive Team

Axoltis Pharma Investors

Notable investors and investment history

Axoltis Pharma investors
InvestorRounds
ODDO BHF GroupSeries A
UI InvestissementSeed
AngelorSeed, Series A
NorfoalkSeries A
Sofimac Investment ManagersSeed, Series A
Capital CellSeries A
UI InvestissementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2026

    Open roles increased to 7, 47% of headcount.

  • Jul 24, 2026

    Monthly visitors increased 6587% MoM, from 30 to 2K.

Axoltis Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axoltis Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axoltis Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersClermont-Ferrand
Employee Range15
Year Founded2003
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?